What ORIGIN Actually Changes in Clinical Practice

By
Published Updated Last reviewed
Clinical medical image for trials origin: What ORIGIN Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |-----------|--------| | N | 12,537 | | Intervention | Insulin glargine titrated to FPG <95 mg/dL | | Comparator | Standard care | | Duration | Median 6.2 years | | Primary endpoint | Composite of CV death, nonfatal MI, nonfatal stroke (coprimary: plus revascularization or hospitalization for heart failure) | | Key result | HR 1.02 (95% CI 0.94, 1.11) for first coprimary; HR 0.63 (0.55, 0.72) for new-onset diabetes |

Why ORIGIN Mattered Before It Reported

Before 2012, clinicians operated under a shadow cast by the ACCORD trial (2008), which linked intensive glucose lowering to excess mortality. The question was simple but unresolved: does exogenous insulin itself cause cardiovascular harm, or was it merely the aggressive glucose targets? Earlier observational data associated insulin use with higher CV event rates, but confounding by indication made interpretation unreliable.

ORIGIN was designed to isolate the insulin variable. By enrolling patients with early dysglycemia (IFG, IGT, or recently diagnosed T2D with minimal prior treatment), the trial removed the confounding of advanced disease and polypharmacy that muddied prior signals. The primary publication randomized 12,537 participants across 573 sites in 40 countries to open-label insulin glargine (target FPG <95 mg/dL) versus standard care.

Methodology Notes That Matter for Translation

Population selection bias toward lower risk. Median A1c at baseline was 6.4%. Over 80% of participants had established cardiovascular disease or risk factors, but their glycemic burden was minimal. This is not the typical insulin-starting population in community practice, where A1c at insulin initiation averages 9 to 10%.

Open-label design. Neither patients nor clinicians were blinded. This introduces performance bias: glargine-group participants received more frequent contact (titration visits), and standard-care participants may have received more aggressive non-insulin therapy to compensate. The trial protocol acknowledges this but argues the pragmatic design reflects real-world prescribing decisions.

Factorial design with omega-3 fatty acids. ORIGIN simultaneously tested omega-3 supplementation (also neutral). The 2x2 factorial structure means some participants received both interventions. No significant interaction was detected, but this adds analytical complexity that secondary analyses must account for.

FPG target of <95 mg/dL. This is tighter than most current basal insulin titration protocols (which target 80 to 130 mg/dL per ADA Standards of Care). The aggressive target contributed to hypoglycemia rates that exceed what clinicians would accept in 2026 practice.

Results Beyond the Headline

HealthRX Practice-Translation Framework for ORIGIN

| Domain | Finding | Clinical Translation | |--------|---------|---------------------| | CV safety | HR 1.02 (0.94, 1.11) for MACE | Insulin glargine carries no intrinsic CV risk signal at normoglycemic targets | | Cancer | HR 1.00 (0.88, 1.13) | No cancer signal, addressing prior glargine concerns from observational studies | | Diabetes prevention | HR 0.63 (0.55, 0.72) for new-onset T2D | 28% relative reduction, but effect did not persist after stopping insulin in ORIGIN extension | | Hypoglycemia | Severe hypo 1.00 vs 0.31 per 100 patient-years | 3x higher rate than standard care; clinically relevant barrier | | Weight | +1.6 kg vs −0.5 kg | Net 2.1 kg difference; modest but consistent with insulin's anabolic effects | | Mortality | HR 0.98 (0.90, 1.08) | No mortality benefit or harm |

What the Neutral Result Actually Means

A neutral result is not a negative result. ORIGIN's primary endpoint data showed the 95% confidence interval excluded a hazard ratio above 1.11. This provides strong evidence against the hypothesis that glargine worsens CV outcomes. For regulatory purposes, this threshold matters: the FDA's 2008 guidance for diabetes drugs requires demonstration that new agents do not increase CV risk by more than 30% (upper CI <1.3 for approval, <1.0 for full safety clearance). Glargine passed both bars easily.

The diabetes prevention finding is mechanistically expected. Exogenous insulin rests beta cells. Once insulin is withdrawn, the underlying pathophysiology reasserts itself. The ORIGIN and GRACE extension study confirmed that the diabetes-prevention benefit attenuated after glargine discontinuation, which is why no guideline body recommends insulin for prediabetes management.

Which Guidelines Actually Changed

ADA Standards of Medical Care. Post-ORIGIN, the ADA explicitly states that basal insulin is CV-neutral. The 2024 Standards note that insulin does not carry the cardiovascular concerns that previously delayed its initiation. This directly counters "clinical inertia" arguments that cited safety fears.

ESC/EASD Joint Guidelines (2019). These European guidelines classify insulin as CV-neutral, placing it below GLP-1RAs and SGLT2 inhibitors (which have proven CV benefit) in the treatment hierarchy for patients with established atherosclerotic disease. ORIGIN's data is the foundation for insulin's neutral classification.

AACE/ACE Consensus Statement. Recommends against withholding insulin due to CV safety fears, citing ORIGIN explicitly. However, it positions insulin below agents with demonstrated CV benefit when atherosclerotic risk drives treatment selection.

What Shifted in Prescribing Patterns

ORIGIN did not make insulin a first-line drug. It removed a barrier. The practical shifts:

  1. Reduced clinical inertia at the insulin-start decision point. Before ORIGIN, some clinicians delayed insulin by 2 to 3 years past guideline-recommended A1c thresholds, partly citing CV uncertainty. Post-ORIGIN, the safety argument for delay weakened.

  2. Repositioned insulin as CV-neutral rather than CV-harmful. This distinction matters when patients ask whether insulin is "dangerous." Clinicians can now cite a 12,537-patient, 6-year trial showing no harm signal.

  3. Did not position insulin for diabetes prevention. Despite the 28% reduction in new-onset diabetes, the transient benefit and hypoglycemia cost made this impractical. Metformin (per DPP trial data) and lifestyle intervention remain the standard prevention approaches.

  4. Informed the CVOT era. ORIGIN preceded the wave of cardiovascular outcome trials (EMPA-REG, LEADER, SUSTAIN-6) that established positive CV signals for newer agents. Without ORIGIN establishing the "neutral" baseline for insulin, the comparative framing of those trials would be different.

Who the Trial Population Was Not

Translating ORIGIN to your patient requires recognizing who was excluded or underrepresented:

  • Patients with A1c >9%. ORIGIN enrolled early dysglycemia. The safety data does not directly address patients starting insulin after prolonged hyperglycemia with A1c of 10 to 12%, who have different atherosclerotic burden and hypoglycemia risk profiles.

  • Patients on multiple oral agents. Most ORIGIN participants were on zero or one oral agent. The modern patient starting basal insulin is typically on metformin plus a second agent, sometimes a third.

  • Patients using second-generation basal insulins. ORIGIN used glargine U-100 (Lantus). Glargine U-300 (Toujeo) and degludec (Tresiba) have flatter pharmacokinetic profiles and lower hypoglycemia rates. The DEVOTE trial confirmed CV neutrality for degludec specifically, extending ORIGIN's principle to the newer analog.

  • Patients where CV benefit (not just neutrality) is the goal. For a patient with established ASCVD, ORIGIN's neutral finding means insulin is safe but not preferred over GLP-1RAs with proven CV benefit.

The Hypoglycemia Cost That Gets Underreported

Severe hypoglycemia occurred at 1.00 events per 100 patient-years in the glargine group versus 0.31 in standard care. Non-severe confirmed hypoglycemia (<54 mg/dL) was substantially more common. The ORIGIN investigators reported that 42% of glargine-group participants experienced at least one confirmed hypoglycemic episode.

This rate reflects the aggressive FPG target (<95 mg/dL). Modern basal insulin titration targets are less stringent. Still, the hypoglycemia data reinforces why insulin remains positioned after agents with lower hypoglycemia risk in current algorithms, even though its CV safety is established.

Bottom Line for 2026 Practice

ORIGIN resolved a question. It did not create a new indication. The trial's lasting contribution is permission: permission to start insulin when indicated without fearing cardiovascular harm, permission to reassure patients that basal insulin is not inherently dangerous, and permission for guidelines to classify insulin as CV-neutral with high-quality evidence rather than assumption. The era of newer agents with CV benefit has since moved the conversation past safety into efficacy, but ORIGIN remains the foundational safety dataset for the world's most prescribed insulin.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. PubMed
  2. ORIGIN Trial Investigators. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care. 2014;37(11):2970-2978. PubMed
  3. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes (DEVOTE). N Engl J Med. 2017;377(8):723-732. PubMed
  4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2020;41(2):255-323. PubMed
  5. American Diabetes Association. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. ADA
  6. Marso SP, Daniels GH, Poulter NR, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. PubMed